Robert Kaplan, Goldman Sachs vice chair and former president of the Federal Reserve Bank of Dallas, expects Kevin Warsh to be an "excellent" Fed chair. Speaking with Julie Fine, Kaplan also discusses the shift in market expectations over the past eight weeks, from anticipating a rate cut later in the year to now considering a possible rate increase or no change due to persistent inflation and elev...
Robert Kaplan, Goldman Sachs vice chair and former president of the Federal Reserve Bank of Dallas, expects Kevin Warsh to be an "excellent" Fed chair. Speaking with Julie Fine, Kaplan also discusses the shift in market expectations over the past eight weeks, from anticipating a rate cut later in the year to now considering a possible rate increase or no change due to persistent inflation and elevated oil prices. (Source: Bloomberg)
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. JPMorgan Chase (NYSE:JPM) has partnered with Cohen & Steers to offer a new hybrid credit fund to clients outside the U.S. through its global wealth platform. The bank has reorganized its investment banking unit, appointing new co heads and adjusting sector coverage to respond to globa...
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. JPMorgan Chase (NYSE:JPM) has partnered with Cohen & Steers to offer a new hybrid credit fund to clients outside the U.S. through its global wealth platform. The bank has reorganized its investment banking unit, appointing new co heads and adjusting sector coverage to respond to global dealmaking activity. In Chicago, JPMorgan is working with Google on a redevelopment of a key downtown commercial area, tying the bank more closely to a high profile urban renewal project. For investors watching large financial institutions, these moves show how JPMorgan Chase is using its wealth platform, investment bank, and real estate footprint together. The new hybrid credit fund offering targets international wealth clients, while the leadership reshuffle focuses the investment bank around current deal flow and sector interest. The Chicago redevelopment with Google also gives NYSE:JPM a visible role in a major urban project, which can matter for local economic activity and the bank's regional presence. Taken together, these updates provide information on how the company is positioning its businesses and physical footprint across markets. Stay updated on the most important news stories for JPMorgan Chase by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on JPMorgan Chase. NYSE:JPM Earnings & Revenue Growth as at May 2026 We've flagged 1 risk for JPMorgan Chase. See which could impact your investment. For you as an investor, these moves point to JPMorgan Chase leaning on partnerships, leadership changes, and real estate decisions to reinforce its core franchises. The Cohen & Steers hybrid credit fund gives the global wealth platform another fixed-income style product tailored to higher-rate conditions, framed as a cash alternative with a focus on short-duration hybrid credit and capital preservation. At the s...
Kevin Warsh, whose broad criticism of current US Federal Reserve officials, playbook for rate cuts and ties to President Donald Trump elevated him past other contenders to lead the central bank, was sworn in as Fed leader on Friday at a pivotal moment for monetary policy and the American economy. Warsh, wearing a dark suit and tie and accompanied by his wife, Jane Lauder, heiress to the Estee La...
Kevin Warsh, whose broad criticism of current US Federal Reserve officials, playbook for rate cuts and ties to President Donald Trump elevated him past other contenders to lead the central bank, was sworn in as Fed leader on Friday at a pivotal moment for monetary policy and the American economy. Warsh, wearing a dark suit and tie and accompanied by his wife, Jane Lauder, heiress to the Estee Lauder fortune, was sworn in by Supreme Court Justice Clarence Thomas after a lengthy introduction by Trump. The White House’s East Room was peppered with top cabinet officials, including Treasury Secretary Scott Bessent, and long-time friends of Warsh, including former secretary of state Condoleezza Rice. Advertisement Trump, who has been incessant in his criticism of former chair Jerome Powell, said Warsh would have the “full support of my administration” and wanted him to be “fully independent” in his new role, but also urged him to recognise that “growth does not mean inflation”. Calling it the “honour of a lifetime to be called back into public service”, Warsh, in brief comments afterward, said: “To fulfil this mission, I will lead a reform-oriented Federal Reserve, learning from past successes and mistakes, both escaping static frameworks and models and upholding clear standards of integrity and performance.” U. Supreme Court justice Clarence Thomas shakes hands with the new Federal Reserve Chair Kevin Warsh, with Warsh’s wife Jane Lauder next to them, at the White House on Friday. Photo: Reuters Awaiting him is an unfolding boom in AI technology that is reshaping the economy in ways Fed officials say could be profound for workers, companies and consumers, but will be hard for Warsh and his colleagues to assess in real time.
The Texas Attorney General has sued Meta over allegations that the company’s WhatsApp messenger, used by more than 3 billion people, doesn’t provide the end-to-end encryption (E2EE) it has long claimed. Since at least 2016, Meta (then named Facebook) has said WhatsApp provides robust end-to-end encryption, meaning that messages are encrypted on a sender’s device with keys that are available only t...
The Texas Attorney General has sued Meta over allegations that the company’s WhatsApp messenger, used by more than 3 billion people, doesn’t provide the end-to-end encryption (E2EE) it has long claimed. Since at least 2016, Meta (then named Facebook) has said WhatsApp provides robust end-to-end encryption, meaning that messages are encrypted on a sender’s device with keys that are available only to the receiver's. By definition, E2EE means that no one else—including the platform itself—can read the plaintext messages. In sworn testimony before two US Senate committees in 2018, CEO Mark Zuckerberg said Meta does “not see any of the content in WhatsApp; it is fully encrypted” and that “Facebook systems do not see the content of messages being transferred over WhatsApp.” The engine for this E2EE is the Signal protocol, an open source code base that multiple third-party experts have said lives up to its promises. Read full article Comments
primeimages/E+ via Getty Images Dear Baron Partners Fund Shareholder, Baron Partners Fund® (the Fund)( BPTIX ) declined 5.33% (Institutional Shares) in the quarter. While disappointed in the absolute return, this result did exceed both its benchmark, the Russell Midcap Growth Index (the Index), and the Morningstar Large Growth Category Average (the Peer Group).* Those two comparative benchmarks de...
primeimages/E+ via Getty Images Dear Baron Partners Fund Shareholder, Baron Partners Fund® (the Fund)( BPTIX ) declined 5.33% (Institutional Shares) in the quarter. While disappointed in the absolute return, this result did exceed both its benchmark, the Russell Midcap Growth Index (the Index), and the Morningstar Large Growth Category Average (the Peer Group).* Those two comparative benchmarks declined 6.35% and 8.44%, respectively. The broader Russell 3000 Index (the Market Index) declined slightly less, falling 3.96% for the quarter. Over the prior 12 months, the Fund has performed quite well on both an absolute and relative basis. In that period, the Fund returned 43.06%. That performance again compares very favorably to the Index, the Market Index, and Peer Group returns of 9.56%, 18.09%, and 16.53%, respectively. Annualized performance (%) for periods ended March 31, 2026 Fund Retail Shares 1,2,3 Fund Institutional Shares 1,2,3,4 Russell Midcap Growth Index 2 Russell 3000 Index 2 QTD 5 (5.39) (5.33) (6.35) (3.96) 1 Year 42.70 43.06 9.56 18.09 3 Years 21.98 22.29 12.74 17.86 5 Years 11.15 11.44 5.37 10.87 10 Years 23.70 24.02 11.69 13.72 15 Years 18.79 19.11 11.12 12.81 Since Conversion(4/30/2003) 17.22 17.45 11.25 11.04 Since Inception(1/31/1992) 15.47 15.62 9.93 10.47 Click to enlarge As of March 31, 2026, the Morningstar Large Growth Category consisted of 1,077, 937, and 763, share classes for the 1-, 5-, and 10-year periods. Morningstar ranked Baron Partners Fund® Institutional Shares in the 2nd, 27th, 1st, 1st, and 1st percentiles for the 1-, 5-, 10-, 15-year, and since conversion periods, respectively. The Fund converted into a mutual fund on April 30, 2003, and the category consisted of 665 share classes. Morningstar calculates the Morningstar Large Growth Category Average performance and rankings using its Fractional Weighting methodology. Morningstar rankings are based on total returns and do not include sales charges. Total returns do account for mana...
Bloomberg’s Ed Ludlow breaks down what comes next after a critical Starship launch was scrubbed, and he discusses what that means for the space company's planned mega IPO with a SpaceX alumni and an early investor. Plus, an exclusive conversation with Lenovo CFO Winston Cheng after the world-leading PC maker soars post-earnings on strong AI growth. (Source: Bloomberg)
Bloomberg’s Ed Ludlow breaks down what comes next after a critical Starship launch was scrubbed, and he discusses what that means for the space company's planned mega IPO with a SpaceX alumni and an early investor. Plus, an exclusive conversation with Lenovo CFO Winston Cheng after the world-leading PC maker soars post-earnings on strong AI growth. (Source: Bloomberg)
Rocket Lab (RKLB +8.80%) stock is rising in Friday's daily trading session. The company's share price was up 7.6% as of 2:10 p.m. ET amid the backdrop of a 0.6% gain for the S&P 500 and a 0.5% gain for the Nasdaq Composite. In addition to bullish momentum for the broader market, Rocket Lab stock is climbing today thanks to a contract win and launch news. The company's share price is now up 94% in ...
Rocket Lab (RKLB +8.80%) stock is rising in Friday's daily trading session. The company's share price was up 7.6% as of 2:10 p.m. ET amid the backdrop of a 0.6% gain for the S&P 500 and a 0.5% gain for the Nasdaq Composite. In addition to bullish momentum for the broader market, Rocket Lab stock is climbing today thanks to a contract win and launch news. The company's share price is now up 94% in 2026 as of this writing. Rocket Lab rises on new contract win After the market closed yesterday, Rocket Lab announced that it had secured a $90 million contract with the U.S. Space Force's Space Systems Command. The new deal will see the company design and operate two geostationary satellites featuring its Heimdall optical payload. The deal is particularly significant because it marks Rocket Lab's first satellite production deal for geostationary orbit applications and sees the company acting as an end-to-end services provider spanning from design, launch, and operations. Expand NASDAQ : RKLB Rocket Lab Today's Change ( 8.80 %) $ 11.04 Current Price $ 136.49 Key Data Points Market Cap $73B Day's Range $ 131.34 - $ 139.74 52wk Range $ 24.67 - $ 139.74 Volume 941.3K Avg Vol 24.2M Gross Margin 33.77 % Rocket Lab notches another successful launch Before the market opened this morning, Rocket Lab published a press release announcing that it completed another successful satellite launch for Synspective. The launch marked the ninth successful launch of Synspective's StriX satellites. With Rocket Lab securing another contract through the U.S. Space Force and delivering another satellite launch, the company has continued to rack up wins and continues to flash strong demand indicators.
Shares of Lenovo soared in Hong Kong trading Friday after the company reported strong growth in AI-related earnings, offsetting challenges from rising component prices. Winston Cheng, CFO of Lenovo, joins Ed Ludlow on "Bloomberg Tech." (Source: Bloomberg)
Shares of Lenovo soared in Hong Kong trading Friday after the company reported strong growth in AI-related earnings, offsetting challenges from rising component prices. Winston Cheng, CFO of Lenovo, joins Ed Ludlow on "Bloomberg Tech." (Source: Bloomberg)
JHVEPhoto/iStock Editorial via Getty Images Novo Nordisk ( NVO ) announced on Friday that an expert panel of the European Medicines Agency, the EU drug regulator, endorsed a single-dose pen containing a 7.2 mg version of its blockbuster obesity therapy Wegovy. Issuing a positive opinion, EMA’s Committee for Medicinal Products for Human Use has recommended marketing authorization for the once-weekl...
JHVEPhoto/iStock Editorial via Getty Images Novo Nordisk ( NVO ) announced on Friday that an expert panel of the European Medicines Agency, the EU drug regulator, endorsed a single-dose pen containing a 7.2 mg version of its blockbuster obesity therapy Wegovy. Issuing a positive opinion, EMA’s Committee for Medicinal Products for Human Use has recommended marketing authorization for the once-weekly injectable in a single-dose pen for weight management in people with obesity. The Danish drugmaker currently markets Wegovy 7.2 mg in the EU for adults with obesity as three separate injections of 2.4 mg. Its approval is based on data from the company’s STEP UP trial program, in which the GLP-1 at the higher dose generated an average weight loss of nearly 21% in people with obesity. “With Wegovy 7.2 mg now recommended for approval in the single-dose pen, people with obesity can reach their weight and health goals through a convenient, easy-to-use pen,” said Mike Doustdar, CEO of Novo ( NVO ). Next, the CHMP recommendation will be reviewed by the European Commission before a final decision on marketing authorization. The company is planning for the EU rollout of Wegovy 7.2 mg in a single-dose pen in Q3 2026. More on Novo Nordisk Novo Nordisk: 2 Reasons To Buy This GLP-1 Giant Novo Nordisk: The First Fruits Of Labor Novo Nordisk: Why I Won't Upgrade Novo Nordisk actively seeking deals to expand pipeline, CEO says Novo Nordisk says oral Wegovy success to soften sales decline
"Bloomberg Real Yield" highlights the market-moving news you need to know. Today's guests: Societe Generale Americas Head of Research Subadra Rajappa, Franklin Templeton Fixed Income CIO Sonal Desai, Capital Group Fixed Income Asset Class Lead Margaret Steinbach, and Baird Funds Co-Chief Investment Officer Warren Pierson. (Source: Bloomberg)
"Bloomberg Real Yield" highlights the market-moving news you need to know. Today's guests: Societe Generale Americas Head of Research Subadra Rajappa, Franklin Templeton Fixed Income CIO Sonal Desai, Capital Group Fixed Income Asset Class Lead Margaret Steinbach, and Baird Funds Co-Chief Investment Officer Warren Pierson. (Source: Bloomberg)
SpaceX delayed a critical test of its massive Starship rocket after a pin tied to the launch tower mechanism failed to retract during the final countdown. The setback comes just a day after the company formally filed for an IPO. Laura Crabtree, CEO of Epsilon3 and former SpaceX engineer, joins Ed Ludlow on "Bloomberg Tech." (Source: Bloomberg)
SpaceX delayed a critical test of its massive Starship rocket after a pin tied to the launch tower mechanism failed to retract during the final countdown. The setback comes just a day after the company formally filed for an IPO. Laura Crabtree, CEO of Epsilon3 and former SpaceX engineer, joins Ed Ludlow on "Bloomberg Tech." (Source: Bloomberg)
Monica Schipper IMAX Corp. ( IMAX ) surged 15% on Friday after the WSJ reported on Thursday that the large-screen theater company is exploring a sale and has approached entertainment firms as possible bidders. The most likely buyers for IMAX include Apple ( AAPL ), Sony ( SONY ), and Netflix ( NFLX ), Wedbush analyst Michael Piccolo wrote in a note on Friday. "The most logical buyers are AAPL, SON...
Monica Schipper IMAX Corp. ( IMAX ) surged 15% on Friday after the WSJ reported on Thursday that the large-screen theater company is exploring a sale and has approached entertainment firms as possible bidders. The most likely buyers for IMAX include Apple ( AAPL ), Sony ( SONY ), and Netflix ( NFLX ), Wedbush analyst Michael Piccolo wrote in a note on Friday. "The most logical buyers are AAPL, SONY, NFLX, or PE firms who can preserve neutrality; and would note a studio acquisition would invite antitrust scrutiny and risk alienating rival distributors," Piccolo wrote. Piccolo expects IMAX shares to establish a new floor in the high $30s to low $40s as traders model potential bid levels. "The ~$1.85B market cap makes IMAX a digestible acquisition for any major studio or private equity, but the central tension is whether a studio buyer would maintain IMAX's vendor-neutral model or favor its own content, which would erode the platform's value to competitors," Piccolo added. More on IMAX IMAX Corporation (IMAX) Presents at J.P. Morgan 54th Annual Global Technology, Media and Communications Conference Transcript IMAX Corporation 2026 Q1 - Results - Earnings Call Presentation IMAX Corporation (IMAX) Q1 2026 Earnings Call Transcript Star Wars' return and busy June slate could extend box office hot streak IMAX jumps on report it's exploring a sale
Justin Sullivan/Getty Images News The US FDA has approved Gilead Sciences' Hepcludex (bulevirtide), the first-ever therapy for chronic hepatitis delta virus (" HDV" ) infection. Approval was based on results from a phase 3 trial that showed combined response was significantly better in those given Hepcludex treatment vs. those given delayed treatment. HDV infection can only occur in individuals wi...
Justin Sullivan/Getty Images News The US FDA has approved Gilead Sciences' Hepcludex (bulevirtide), the first-ever therapy for chronic hepatitis delta virus (" HDV" ) infection. Approval was based on results from a phase 3 trial that showed combined response was significantly better in those given Hepcludex treatment vs. those given delayed treatment. HDV infection can only occur in individuals with hepatitis B virus. Hepcludex received Breakthrough Therapy and Orphan Drug designations. The treatment was approved in the European Union in 2020 and in Canada in 2025. More on Gilead Sciences Why Gilead Sciences Is Now A Hold (Rating Upgrade) Gilead Sciences, Inc. (GILD) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript Gilead's Transition Into A Long-Duration Biotech Platform AbbVie, Merck, Astra among winners of EU drug recommendations this week FDA leadership fallout continues as acting CDER Director Hoeg departs